SCHEMBL3975864

SCHEMBL3975864

Nc1ccc(CC(=O)NS(=O)(=O)Cc2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.52
CA1 P00915 4/20 0.49
CA2 P00918 4/20 0.49
MMP1 P03956 1/20 0.49
MMP2 P08253 1/20 0.49
MMP9 P14780 1/20 0.49
MMP8 P22894 1/20 0.49
MMP13 P45452 1/20 0.49
SIGMAR1 Q99720 1/20 0.48
EGFR P00533 4/20 0.48
ERBB2 P04626 4/20 0.48
PTGER4 P35408 1/20 0.47
CA5A P35218 3/20 0.47
CA7 P43166 3/20 0.47
CA5B Q9Y2D0 3/20 0.47
CA12 O43570 2/20 0.47
CA9 Q16790 2/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
HDAC8 Q9BY41 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975862 0.85 PLA2G10 (0.53) CA1CA2MMP1MMP2MMP9
SCHEMBL3936655 0.80 CA1 (0.58) CA1CA2MMP1MMP2MMP9
SCHEMBL3975407 0.80 EGFR (0.73) EGFRERBB2KMT2AMEN1HDAC8
SCHEMBL3978340 0.77 EGFR (0.42) CNR2CA1CA2EGFRERBB2
SCHEMBL9911079 0.77 ACLY (0.50) CA1CA2MMP1MMP2MMP9
SCHEMBL30361414 0.76 CA2 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL8163200 0.76 MMP1 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL21887555 0.76 PDE4B (0.46) CNR2EGFRERBB2GLSALDH1A1
SCHEMBL10494718 0.76 CA2 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL27796626 0.75 CA1 (0.57) CA1CA2EGFRERBB2CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569602-B2 Furan derivatives as EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2009-08-04 US disclosed
EP-1673360-B1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LTD (GB) 2008-12-17 EP disclosed
US-20080306117-A1 EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2008-12-11 US disclosed
US-7417068-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2008-08-26 US disclosed
US-20070135503-A1 Furan derivatives as ep4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2007-06-14 US disclosed
EP-1673360-A1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2006-06-28 EP disclosed
US-20050124676-A1 EP4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2005-06-09 US disclosed
WO-2005037812-A1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124676-A1 EP4 receptor antagonists PTGER4, PTGER3, NR4A3 CNR2 23/4885CA1 2117/4885CA2 2067/4885
US-20080306117-A1 EP4 RECEPTOR ANTAGONISTS PTGER4, PTGER3, NR4A3 CNR2 23/4885CA1 2117/4885CA2 2067/4885
US-20070135503-A1 Furan derivatives as ep4 receptor antagonists PTGER4, PTGER3, NR4A3 CNR2 34/4885CA1 1728/4885CA2 1650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.